1118 related articles for article (PubMed ID: 29972757)
1. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
[TBL] [Abstract][Full Text] [Related]
2. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
[TBL] [Abstract][Full Text] [Related]
3. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
Coelho T; Marques W; Dasgupta NR; Chao CC; Parman Y; França MC; Guo YC; Wixner J; Ro LS; Calandra CR; Kowacs PA; Berk JL; Obici L; Barroso FA; Weiler M; Conceição I; Jung SW; Buchele G; Brambatti M; Chen J; Hughes SG; Schneider E; Viney NJ; Masri A; Gertz MR; Ando Y; Gillmore JD; Khella S; Dyck PJB; Waddington Cruz M;
JAMA; 2023 Oct; 330(15):1448-1458. PubMed ID: 37768671
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.
Brannagan TH; Coelho T; Wang AK; Polydefkis MJ; Dyck PJ; Berk JL; Drachman B; Gorevic P; Whelan C; Conceição I; Plante-Bordeneuve V; Merlini G; Obici L; Plana JMC; Gamez J; Kristen AV; Mazzeo A; Gentile L; Narayana A; Olugemo K; Aquino P; Benson MD; Gertz M;
J Neurol; 2022 Dec; 269(12):6416-6427. PubMed ID: 35908242
[TBL] [Abstract][Full Text] [Related]
5. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.
Coelho T; Yarlas A; Waddington-Cruz M; White MK; Sikora Kessler A; Lovley A; Pollock M; Guthrie S; Ackermann EJ; Hughes SG; Karam C; Khella S; Gertz M; Merlini G; Obici L; Schmidt HH; Polydefkis M; Dyck PJB; Brannagan Iii TH; Conceição I; Benson MD; Berk JL
J Neurol; 2020 Apr; 267(4):1070-1079. PubMed ID: 31853709
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment for familial amyloid polyneuropathy.
Magrinelli F; Fabrizi GM; Santoro L; Manganelli F; Zanette G; Cavallaro T; Tamburin S
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012395. PubMed ID: 32311072
[TBL] [Abstract][Full Text] [Related]
7. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.
Brannagan TH; Wang AK; Coelho T; Waddington Cruz M; Polydefkis MJ; Dyck PJ; Plante-Bordeneuve V; Berk JL; Barroso F; Merlini G; Conceição I; Hughes SG; Kwoh J; Jung SW; Guthrie S; Pollock M; Benson MD; Gertz M;
Eur J Neurol; 2020 Aug; 27(8):1374-1381. PubMed ID: 32343462
[TBL] [Abstract][Full Text] [Related]
8. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
[No Abstract] [Full Text] [Related]
9. Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study.
Yarlas A; Lovley A; Brown D; Kosinski M; Vera-Llonch M
J Neurol; 2022 Jan; 269(1):323-335. PubMed ID: 34125267
[TBL] [Abstract][Full Text] [Related]
10. Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.
Yarlas A; Lovley A; McCausland K; Brown D; Vera-Llonch M; Conceição I; Karam C; Khella S; Obici L; Waddington-Cruz M
Neurol Ther; 2021 Dec; 10(2):865-886. PubMed ID: 34355354
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen.
Karam C; Brown D; Yang M; Done N; Dieye I; Bozas A; Vera Llonch M; Signorovitch J
Muscle Nerve; 2022 Sep; 66(3):319-328. PubMed ID: 35766224
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial.
Karam C; Brown D; Yang M; Done N; Zhu JJ; Greatsinger A; Bozas A; Vera-Llonch M; Signorovitch J
Muscle Nerve; 2022 Oct; 66(4):438-446. PubMed ID: 35799473
[TBL] [Abstract][Full Text] [Related]
13. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L
Coelho T; Ando Y; Benson MD; Berk JL; Waddington-Cruz M; Dyck PJ; Gillmore JD; Khella SL; Litchy WJ; Obici L; Monteiro C; Tai LJ; Viney NJ; Buchele G; Brambatti M; Jung SW; St L O'Dea L; Tsimikas S; Schneider E; Geary RS; Monia BP; Gertz M
Neurol Ther; 2021 Jun; 10(1):375-389. PubMed ID: 33638113
[TBL] [Abstract][Full Text] [Related]
14. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
Benson MD; Dasgupta NR; Monia BP
Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247
[TBL] [Abstract][Full Text] [Related]
15. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
[TBL] [Abstract][Full Text] [Related]
16. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.
Dyck PJB; Kincaid JC; Wiesman JF; Polydefkis M; Litchy WJ; Mauermann ML; Ackermann EJ; Guthrie S; Pollock M; Jung SW; Baker BF; Dyck PJ
Muscle Nerve; 2020 Oct; 62(4):502-508. PubMed ID: 32654212
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
[TBL] [Abstract][Full Text] [Related]
18. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
Dyck PJB; Coelho T; Waddington Cruz M; Brannagan TH; Khella S; Karam C; Berk JL; Polydefkis MJ; Kincaid JC; Wiesman JF; Litchy WJ; Mauermann ML; Ackermann EJ; Baker BF; Jung SW; Guthrie S; Pollock M; Dyck PJ
Muscle Nerve; 2020 Oct; 62(4):509-515. PubMed ID: 32654156
[TBL] [Abstract][Full Text] [Related]
19. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
Luigetti M; Antonini G; Di Paolantonio A; Gentile L; Grandis M; Leonardi L; Lozza A; Manganelli F; Mazzeo A; Mussinelli R; My F; Obici L; Maria Pennisi E; Romozzi M; Russo M; Sabatelli M; Salvalaggio A; Tagliapietra M; Tozza S
Eur J Neurol; 2022 Jul; 29(7):2148-2155. PubMed ID: 35289020
[TBL] [Abstract][Full Text] [Related]
20. Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.
Narayanan P; Curtis BR; Shen L; Schneider E; Tami JA; Paz S; Burel SA; Tai LJ; Machemer T; Kwoh TJ; Xia S; Shattil SJ; Witztum JL; Engelhardt JA; Henry SP; Monia BP; Hughes SG
Nucleic Acid Ther; 2020 Apr; 30(2):94-103. PubMed ID: 32043907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
